Upfront Briefing
Biotech had one of those rare days where it ignored the broad tape and minded its own catalysts. XBI outpaced the majors on an FDA double-header — Gilead's Trodelvy cleared first-line TNBC and Ionis' Tryngolza became the first therapy shown to cut pancreatitis risk in severe hypertriglyceridemia — while GSK pulled the trigger on its $10.6B Nuvalent buyout, formally launching the tender offer.
Elsewhere, dealmaking kept moving through every lane: reverse mergers, public paper, a hefty private round for late-stage ophthalmology, and Novartis writing a $105M check to go after "undruggable" cancer targets.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,358.2 |
(0.1%) |
7.3% |
| Nasdaq 100 |
29,220.1 |
(0.4%) |
15.9% |
| Russell 2000 |
2,986.6 |
0.4% |
19.1% |
| Healthcare (XLV) |
153.4 |
0.8% |
(1.4%) |
| Biotech (XBI) |
149.7 |
1.8% |
23.2% |
| Nasdaq Biotech (NBI) |
6,279.4 |
1.5% |
10.0% |
| Clinical Trials (BBC) |
49.2 |
1.4% |
30.6% |
|
- Biotech kept the bid while broad tech sagged — XBI up 1.8% versus the Nasdaq 100 down 0.4% — as a same-day FDA double-header (Trodelvy, Tryngolza) and the GSK/Nuvalent tender launch gave the sector its own script.
- The broad tape gave back early gains as energy and semis dragged — Brent crude sank 4.3% to ~$73.74 on Strait of Hormuz de-escalation and the 10-year yield slipped below 4.5%, with investors playing defense into Micron's after-hours print.
- Market data: U.S. cash close Wednesday, 24 June 2026.
The Big 3
|
1
|
FDA approves broader Tryngolza use in severe hypertriglyceridemia
|
-
Tryngolza won expanded FDA approval for adults with severe hypertriglyceridemia — cleared to lower triglycerides and reduce the risk of acute pancreatitis, moving Ionis beyond its prior familial chylomicronemia syndrome niche.
-
Why it matters: This is Ionis' first solo launch into a prevalent indication — sHTG hits more than 3 million U.S. adults (~1 million high-risk) versus the narrow FCS niche Tryngolza launched in. The label rests on a genuine first: up to ~91% fewer acute-pancreatitis events and up to 72% triglyceride lowering in CORE/CORE2, with no rival carrying a pancreatitis-risk claim. Jefferies pegs peak sales near $2.5B, roughly $1.5B from sHTG alone. Arrowhead's plozasiran (Redemplo) is the competitive watch item. Approval landed ahead of the June 30 PDUFA; U.S. availability is slated for July, so the read from here is execution.
-
Source:
HCPLive
-
More:
Precision Medicine;
Ionis
|
| 2 | FDA clears Trodelvy for two first-line TNBC settings |
-
Trodelvy won FDA approval in two first-line metastatic TNBC settings — monotherapy for patients ineligible for PD-1/PD-L1 therapy, and in combination with pembrolizumab for PD-L1-positive disease — pushing the ADC into frontline use.
-
Why it matters: Front-line metastatic TNBC is a far larger pool than the later-line setting where Trodelvy already leads, and Gilead now holds both lanes — monotherapy for PD-(L)1-ineligible patients (ASCENT-03, n=558) and a Keytruda combo for PD-L1-positive disease (ASCENT-04/KEYNOTE-D19, n=443). It lands about a month after Daiichi/AstraZeneca's Datroway cleared a narrower first-line TNBC indication, so Gilead's broader, across-PD-L1 label is the competitive tell. With 75,000+ patients already treated, the approval steepens Trodelvy's revenue curve and resets the bar for Trop-2 and rival ADCs trying to win share earlier in care.
-
Source:
Endpoints
-
More:
FDA;
Gilead
|
|
3
|
GSK pulls the trigger on its $10.6B Nuvalent tender offer
|
-
GSK formally commenced its all-cash tender offer for Nuvalent on June 24 at $124 per share — a 40% premium — putting the $10.6B buyout ($9.4B net of cash) on the clock; the offer expires July 14.
-
Why it matters: The launch turns a signed agreement into a countdown — structured under DGCL 251(h) to skip a shareholder vote. GSK is paying up for line-of-sight: zidesamtinib (ROS1) and neladalkib (ALK) carry PDUFA dates of Sept 18 and Nov 27 and could launch this year, with HER2 asset NVL-330 behind them. The strategic driver is the 2028 dolutegravir cliff against a ~$3.6B HIV franchise. It's CEO Luke Miels' first big swing and GSK's largest deal since the 2014 Novartis swap; at $10.6B it sets a fresh comp for late-stage targeted-oncology takeouts and leaves little margin for launch slips.
-
Source:
Endpoints
-
More:
GSK;
Bloomberg
|
Everything Else that broke
- FDA TrialBlazer reforms may speed U.S. starts, but China still holds advantages in trial execution. — BioCentury
- Acting FDA leaders are trying to rebuild staff and industry trust after recent turmoil. — Endpoints
- FDA cited delayed mold investigation and quality lapses in a warning letter to Jubilant HollisterStier. — BioSpace
- ADC Therapeutics cut 17% of staff, or about 30 workers, after the Zynlonta setback. — BioSpace
- A former employee sued BioNTech over alleged protocol deviations in two pancreatic cancer trials. — Endpoints
- Innovative Molecules dosed the first patient in a Phase 2a trial of adibelivir (IM-250). — PR
- The Lancet published AnaCardio's Phase 1b/2a GOAL-HF1 study of AC01 in HFrEF. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Novartis / Antares — oncology discovery pact, $105M upfront, up to $1.8B option fees + milestones, tiered royalties. — Fierce Biotech
- Passage Bio will hand RNA specialist Remix a Nasdaq listing (ticker RMTX) via all-stock reverse merger paired with a ~$100M PIPE; Passage holders keep 7%, and the combined company is funded into 2028. — Fierce Biotech
- Lilly invested in Absci to work on hair-loss treatments. — STAT
- Cityblock is in talks to acquire Homeward Health, combining two General Catalyst-backed startups. — Endpoints
VC / Private Financings
- Ollin raised an oversubscribed $330M Series B, co-led by TCGX and ARCH Venture Partners, for IBI324 Phase 3. — PR
IPOs / Follow-Ons
- Taysha priced a $200M public offering at $6.00 per share plus 833,333 pre-funded warrants. — PR
Academic Corner - Hospital-policy tranexamic acid reduced transfusions in major noncardiac surgery and was noninferior on venous thromboembolism at 90 days. — NEJM
- A NEJM review said early peanut introduction and early immunotherapy improve prevention and treatment outcomes. — NEJM
- Nature Medicine published Talos, an automated genomic reanalysis tool for rare-disease diagnostics at scale. — Nature Medicine
|
